Given that metformin appears to act on a subpopulation of tumor stem cells, it seems reasonable that more aggressive breast cancer subtypes enriched with CSC-like features, such as basal-like (triple negative) and HER2 cells, would be more sensitive to the action of metformin [88]. Here, ERBB2 is linked to breast carcinoma.